Literature DB >> 6969403

ATP depletion as a consequence of adenosine deaminase inhibition in man.

M F Siaw, B S Mitchell, C A Koller, M S Coleman, J J Hutton.   

Abstract

Hereditary deficiency of the enzyme adenosie deaminase (adenosine aminohydrolase, EC 3.5.4.4) results in an immunodeficiency syndrome characterized by a marked reduction in circulating lymphocytes. We have administered 2'-deoxycoformycin, a potent inhibitor of adenosine deaminase, to a patient with a lymphoproliferative malignancy. The clinical consequences of pharmacologic inhibition of adenosine deaminase activity included an abrupt decrease in the lymphocyte count, abnormalities of renal and hepatic function, and hemolytic anemia. The plasma concentrations of adenosine and deoxyadenosine rose to peak values of 13 microM and 5 microM, respectively, and erythrocyte dATP levels increased to 110 pmol/10(6) cells over 9 days. There was a corresponding decrease in erythrocyte ATP levels from 128 to < 6 pmol/10(6) cells. A similar profound reductin in ATP occurred in the erythrocytes of a second patient. The rapid and unexpected depletion of ATP associated with dATP accumulation may account, at least in part, for the toxicity associated with 2'-deoxycoformycin administration. The inverse relationship of ATP and dATP raises major questions about the control of energy metabolism in erythrocytes.

Entities:  

Mesh:

Substances:

Year:  1980        PMID: 6969403      PMCID: PMC350233          DOI: 10.1073/pnas.77.10.6157

Source DB:  PubMed          Journal:  Proc Natl Acad Sci U S A        ISSN: 0027-8424            Impact factor:   11.205


  29 in total

Review 1.  Incorporation of analog purine nucleosides into the formed elements of human blood: erythrocytes, platelets, and lymphocytes.

Authors:  R E Parks; G W Crabtree; C M Kong; R P Agarwal; K C Agarwal; E M Scholar
Journal:  Ann N Y Acad Sci       Date:  1975-08-08       Impact factor: 5.691

2.  Incorporation of nucleosides into the nucleotide pools of human erythrocytes. Adenosine and its analogs.

Authors:  R E Parks; P R Brown
Journal:  Biochemistry       Date:  1973-08-14       Impact factor: 3.162

3.  A method for the determination of dATP and dTTP in picomole amounts.

Authors:  U Lindberg; L Skoog
Journal:  Anal Biochem       Date:  1970-03       Impact factor: 3.365

4.  Adenosine-deaminase deficiency in two patients with severely impaired cellular immunity.

Authors:  E R Giblett; J E Anderson; F Cohen; B Pollara; H J Meuwissen
Journal:  Lancet       Date:  1972-11-18       Impact factor: 79.321

5.  Molecular form of adenosine deaminase in severe combined immunodeficiency.

Authors:  M B Van der Weyden; R H Buckley; W N Kelley
Journal:  Biochem Biophys Res Commun       Date:  1974-04-08       Impact factor: 3.575

6.  Deoxyadenosine metabolism and toxicity in cultured L5178Y cells.

Authors:  J K Lowe; B Gowans; L Brox
Journal:  Cancer Res       Date:  1977-09       Impact factor: 12.701

7.  Hereditary hemolytic anemia with increased red cell adenosine deaminase (45- to 70-fold) and decreased adenosine triphosphate.

Authors:  W N Valentine; D E Paglia; A P Tartaglia; F Gilsanz
Journal:  Science       Date:  1977-02-25       Impact factor: 47.728

8.  Combined immunodeficiency disease associated with adenosine deaminase deficiency. Report on a workshop held in Albany, New York, October 1, 1973.

Authors:  H J Meuwissen; B Pollara; R J Pickering
Journal:  J Pediatr       Date:  1975-02       Impact factor: 4.406

9.  Enzyme replacement therapy for adenosine deaminase deficiency and severe combined immunodeficiency.

Authors:  S H Polmar; R C Stern; A L Schwartz; E M Wetzler; P A Chase; R Hirschhorn
Journal:  N Engl J Med       Date:  1976-12-09       Impact factor: 91.245

10.  Doxynucleotide-polymerizing enzymes of calf thymus gland. IV. Inhibition of terminal deoxynucleotidyl transferase by metal ligands.

Authors:  L M Chang; F J Bollum
Journal:  Proc Natl Acad Sci U S A       Date:  1970-04       Impact factor: 11.205

View more
  19 in total

1.  Mechanism of deoxyadenosine and 2-chlorodeoxyadenosine toxicity to nondividing human lymphocytes.

Authors:  S Seto; C J Carrera; M Kubota; D B Wasson; D A Carson
Journal:  J Clin Invest       Date:  1985-02       Impact factor: 14.808

2.  Factors influencing the inhibition of repair of irradiation-induced DNA damage by 2'-deoxycoformycin and deoxyadenosine.

Authors:  A Begleiter; L Verburg; L G Israels; J B Johnston
Journal:  Cancer Chemother Pharmacol       Date:  1992       Impact factor: 3.333

Review 3.  Adenosine and adenosine receptors in immune function. Minireview and meeting report.

Authors:  R B Gilbertsen
Journal:  Agents Actions       Date:  1987-10

4.  Adenosine kinase deficiency in tritiated deoxyadenosine-resistant mouse S49 lymphoma cell lines.

Authors:  K J Sastry; C Huang; T S Chan
Journal:  Biochem Genet       Date:  1987-12       Impact factor: 1.890

5.  Purinogenic lymphocytotoxicity: clues to a wider chemotherapeutic potential for the adenosine deaminase inhibitors.

Authors:  R F Kefford; R M Fox
Journal:  Cancer Chemother Pharmacol       Date:  1983       Impact factor: 3.333

6.  Extracellular guanosine regulates extracellular adenosine levels.

Authors:  Edwin K Jackson; Dongmei Cheng; Travis C Jackson; Jonathan D Verrier; Delbert G Gillespie
Journal:  Am J Physiol Cell Physiol       Date:  2012-12-12       Impact factor: 4.249

Review 7.  Metabolic defects in immunodeficiency diseases.

Authors:  A D Webster
Journal:  Clin Exp Immunol       Date:  1982-07       Impact factor: 4.330

8.  Biochemical and functional abnormalities in lymphocytes from an adenosine deaminase-deficient patient during enzyme replacement therapy.

Authors:  J J Hutton; D A Wiginton; M S Coleman; S A Fuller; S Limouze; B C Lampkin
Journal:  J Clin Invest       Date:  1981-08       Impact factor: 14.808

9.  Mechanism of deoxyadenosine-induced catabolism of adenine ribonucleotides in adenosine deaminase-inhibited human T lymphoblastoid cells.

Authors:  A S Bagnara; M S Hershfield
Journal:  Proc Natl Acad Sci U S A       Date:  1982-04       Impact factor: 11.205

10.  Antileukemic and immunosuppressive activity of 2-chloro-2'-deoxyadenosine.

Authors:  D A Carson; D B Wasson; E Beutler
Journal:  Proc Natl Acad Sci U S A       Date:  1984-04       Impact factor: 11.205

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.